Antibiotic formulations for lower back pain
AssigneePersica Pharmaceuticals Ltd.
InventorsLloyd Czaplewski, Sarah Guest
Life of this patent
Estimating the term…
Abstract
The present invention relates to injectable compositions. More particularly, the present disclosure relates to injectable, thermogelling hydrogel formulations comprising at least one antibiotic for relieving and/or treating low back pain.
Claims21
A method of treating lower back pain in a subject, the method comprising administering to the subject an injectable pharmaceutical composition, wherein the injectable pharmaceutical composition comprises:
- (a) an effective amount of linezolid, wherein the linezolid is present in an amount of from about 2.5% to about 20% by weight of the injectable pharmaceutical composition;
- (b) a thermosensitive hydrogel which is poloxamer 407, wherein said poloxamer 407 is present in an amount of from about 2% to about 20% by weight of the injectable pharmaceutical composition;
- (c) a radio-contrast agent iohexol;
- and
- (d) optionally, at least one pharmaceutically acceptable excipient;
- wherein the linezolid forms a micro suspension or a nanosuspension in the injectable pharmaceutical composition, and wherein the injectable pharmaceutical composition is administered to the subject by injection to a lumbar intervertebral disc and/or the adjacent vertebrae or joints.
A method of simultaneously (1) relieving or ameliorating lower back pain in a subject and (2) eliminating a bacterial infection in a lumbar intervertebral disc, lumbar intervertebral space and/or lumbar vertebra in the subject, the method comprising administering to the subject an injectable pharmaceutical composition, wherein the injectable pharmaceutical composition comprises:
- (a) an effective amount of linezolid, wherein the linezolid is present in an amount of from about 2.5% to about 20% by weight of the injectable pharmaceutical composition;
- (b) a thermosensitive hydrogel which is poloxamer 407, wherein said poloxamer 407 is present in an amount of from about 2% to about 20% by weight of the injectable pharmaceutical composition;
- (c) a radio-contrast agent iohexol;
- and
- (d) optionally, at least one pharmaceutically acceptable excipient;
- wherein the linezolid forms a micro suspension or a nanosuspension in the injectable pharmaceutical composition, and wherein the injectable pharmaceutical composition is administered to the subject by injection to a lumbar intervertebral disc and/or the adjacent vertebrae or joints.
Dependencies are inferred from the claim text.